Baker McKenzie partners with Lundbeck in-house legal team on the $1.95 Billion Transaction

Baker McKenzie is advising global pharmaceutical company Lundbeck on the acquisition of Alder BioPharmaceuticals, a company committed to migraine treatment and prevention. The transaction is valued up to $1.95 billion net of cash, on a fully diluted basis.

This acquisition will further enhance Lundbeck's capabilities to deliver future biological innovations in brain diseases. The addition of eptinezumab, which Alder is developing for preventive migraine treatment, will expand Lundbeck’s leading global brain disease franchise. 

Lundbeck's in-house legal team advising on the transaction was led by Lundbeck's general counsel Søren Hoffmann, and includes Allan Normann, Thomas Forrester and Colleen Hickey.

Baker McKenzie's team advising Lundbeck is led by Thomas Hughes, M&A, and Randall Sunberg, North America Life Science Practice Co-Head, and includes Piotr Korzynski, Jonathan Farrokhnia, Geoffrey Hainbach, Collin Stich and Rebecca Chang (M&A), Andrew Haupt (Life Sciences), Craig Roeder and Michael Hamilton (Capital Markets), Dr. Jur Strobos and Thilo Raepple (Regulatory), Pamela Church, Heiko Burow and Jessica Greenwald (Intellectual Property), Maura Ann McBreen and Carole Spink (Employee Benefits and Labor), Creighton Macy, Christian Burholdt and Andreas Traugott (Antitrust), and Kai Kramer and Ross Staine (Tax). 

Baker McKenzie's Healthcare and Life Sciences group advises many of the world's largest pharmaceutical, biotech, medical device and healthcare services companies on a range of issues including transactional matters, patents and brands, global transfer pricing and tax planning strategies, product liability, competition and trade, commercial agreements, data privacy, employment issues and market entry. 

This year, LMG Life Sciences, a guide to the leading North American law firms in the industry, named Baker McKenzie a 2019 Financial & Corporate Firm to Watch, noting our work in licensing, collaboration, M&A and venture capital.


About Baker McKenzie

Baker McKenzie is one of the leading firms for cross-border transactions, providing strategic advice on deals involving the world’s leading financial institutions and multinational companies. From deal inception to business integration, we provide an end-to-end service that helps clients bridge the gap between aspiration and achievement.

Baker McKenzie helps clients overcome the challenges of competing in the global economy. We solve complex legal problems across borders and practice areas. Our unique culture, developed over 65 years, enables our 13,000 people to understand local markets and navigate multiple jurisdictions, working together as trusted colleagues and friends to instil confidence in our clients.

Explore Our Newsroom